Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$3.08
+2.3%
$3.50
$1.21
▼
$3.81
$76.07M0.68261,100 shs489,201 shs
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
$1.81
-4.7%
$2.31
$1.70
▼
$14.85
$18.06M1.38111,283 shs42,714 shs
Equillium, Inc. stock logo
EQ
Equillium
$1.10
-9.1%
$1.54
$0.81
▼
$3.54
$90.55M2.08601,628 shs889,904 shs
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$1.91
-4.5%
$2.04
$1.56
▼
$3.85
$75.96M1.1444,497 shs10,451 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-1.63%-6.52%+4.15%-36.76%+40.65%
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-2.46%-11.21%-34.71%-28.03%-83.86%
Equillium, Inc. stock logo
EQ
Equillium
+5.22%-16.84%+1.68%-48.07%+15.24%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
+3.09%+0.50%-2.91%+0.50%-34.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$3.08
+2.3%
$3.50
$1.21
▼
$3.81
$76.07M0.68261,100 shs489,201 shs
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
$1.81
-4.7%
$2.31
$1.70
▼
$14.85
$18.06M1.38111,283 shs42,714 shs
Equillium, Inc. stock logo
EQ
Equillium
$1.10
-9.1%
$1.54
$0.81
▼
$3.54
$90.55M2.08601,628 shs889,904 shs
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$1.91
-4.5%
$2.04
$1.56
▼
$3.85
$75.96M1.1444,497 shs10,451 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-1.63%-6.52%+4.15%-36.76%+40.65%
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-2.46%-11.21%-34.71%-28.03%-83.86%
Equillium, Inc. stock logo
EQ
Equillium
+5.22%-16.84%+1.68%-48.07%+15.24%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
+3.09%+0.50%-2.91%+0.50%-34.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.00
N/AN/AN/A
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
2.50
Moderate Buy$20.331,023.39% Upside
Equillium, Inc. stock logo
EQ
Equillium
2.92
Moderate Buy$7.13547.73% Upside
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
2.67
Moderate Buy$5.50187.96% Upside

Current Analyst Ratings Breakdown

Latest ATOS, SERA, EQ, and AADI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Equillium, Inc. stock logo
EQ
Equillium
Reiterated RatingStrong-Buy
11/13/2026
Equillium, Inc. stock logo
EQ
Equillium
Set Price TargetBuy$4.00
11/2/2026
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
DowngradeSell (D-) ➝ Sell (E+)
10/26/2026
Equillium, Inc. stock logo
EQ
Equillium
Reiterated RatingBuy
10/14/2026
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
UpgradeSell (E+) ➝ Sell (D-)
10/12/2026
Equillium, Inc. stock logo
EQ
Equillium
Initiated CoverageOutperform$6.00
9/25/2026
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
DowngradeSell (D-) ➝ Sell (E+)
9/21/2026
Equillium, Inc. stock logo
EQ
Equillium
Reiterated RatingSell (D-)
9/10/2026
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
UpgradeSell (E+) ➝ Sell (D-)
9/8/2026
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
Reiterated RatingSell (E+)
9/4/2026
Equillium, Inc. stock logo
EQ
Equillium
Reiterated RatingBuy$12.00
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$25.07M3.03N/AN/A$4.29 per share0.72
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/AN/AN/AN/A$2.18 per shareN/A
Equillium, Inc. stock logo
EQ
Equillium
$41.10M2.20N/AN/A$0.64 per share1.72
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$80K949.51N/AN/A$1.32 per share1.45
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%N/A
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-$34.77M-$3.11N/AN/AN/AN/A-117.07%-96.08%N/A
Equillium, Inc. stock logo
EQ
Equillium
-$22.40M-$0.18N/AN/AN/AN/A-37.33%-35.07%N/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$31.93M-$0.67N/AN/AN/A-34,866.67%-52.54%-36.97%N/A

Latest ATOS, SERA, EQ, and AADI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Equillium, Inc. stock logo
EQ
Equillium
-$0.0490-$0.04+$0.0090-$0.04N/AN/A
11/10/2026Q3 2026
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-$0.8567-$0.56+$0.2967-$0.56N/AN/A
11/4/2026Q3 2026
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$0.14-$0.16-$0.02-$0.16$0.08 million$0.04 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/AN/AN/AN/AN/A
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/AN/AN/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/A
4.89
4.54
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/A
5.35
5.35
Equillium, Inc. stock logo
EQ
Equillium
N/A
19.49
19.49
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/A
1.88
1.88

Institutional Ownership

CompanyInstitutional Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
52.08%
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
12.74%
Equillium, Inc. stock logo
EQ
Equillium
27.05%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
54.64%

Insider Ownership

CompanyInsider Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
37.30%
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
9.80%
Equillium, Inc. stock logo
EQ
Equillium
17.84%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
11.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
4024.70 million15.49 millionNo Data
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
149.98 million9.00 millionOptionable
Equillium, Inc. stock logo
EQ
Equillium
1482.32 million64.39 millionOptionable
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
7239.77 million35.28 millionOptionable

Recent News About These Companies

Sera: 3 key takeaways for long-term investors
Sera Prognostics (SERA) Q3 2026 Earnings Call Transcript
Sera Prognostics (NASDAQ:SERA) Issues Earnings Results
Sera Prognostics (NASDAQ:SERA) CEO Sells $40,278.00 in Stock
Sera (SERA) Q2 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aadi Bioscience stock logo

Aadi Bioscience NASDAQ:AADI

$3.08 +0.07 (+2.33%)
As of 11/17/2026

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Atossa Genetics stock logo

Atossa Genetics NASDAQ:ATOS

$1.81 -0.09 (-4.74%)
Closing price 04:00 PM Eastern
Extended Trading
$1.81 +0.00 (+0.06%)
As of 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Equillium stock logo

Equillium NASDAQ:EQ

$1.10 -0.11 (-9.09%)
Closing price 04:00 PM Eastern
Extended Trading
$1.10 0.00 (-0.27%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Sera Prognostics stock logo

Sera Prognostics NASDAQ:SERA

$1.91 -0.09 (-4.50%)
Closing price 04:00 PM Eastern
Extended Trading
$1.92 +0.01 (+0.52%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.